eliminated on treatment with fibrates. 28 However, patients with idiopathic dilated cardiomyopathy had reduced myocardial FFA uptake, which was inversely associated with left ventricular (LV) ejection fraction (LVEF). 29 Elevated concentrations of FFAs may lead to increased myocardial FFA uptake, increased triglycerides synthesis, and fat storage within cardiomyocytes, with resulting lipotoxicity, 30 apoptosis, and perhaps LV dysfunction. It is not clear whether plasma levels of FFAs in apparently healthy adults are associated with incident HF. Hence, the current project sought to evaluate the association between plasma FFAs and incident HF in older US adults.
Methods

Study Population
The Cardiovascular Health Study (CHS) is a prospective cohort consisting of 5888 men and women ≥65 years old who were selected for recruitment from 4 US communities (Forsyth County, NC; Washington County, MD; Sacramento County, CA; and Pittsburgh, PA). A detailed description of methods and procedures in the CHS has been previously published. 31 Briefly, between 1989 and 1990, a total of 5201 men and women ≥65 years old were enrolled. In addition, a supplemental cohort of 687 predominantly black men and women was recruited between 1992 and 1993 from 3 of the same communities (excepting Washington County) using similar sampling and recruitment methods. Of the 5265 participants who attended the 1992 to 1993 visit, we excluded participants with prevalent HF (n=436), missing plasma FFA measurement (n=395), or missing covariate data (n=186), resulting in a final analysis sample of 4248 participants. The institutional review board of each participating center approved the study, and all participants gave informed written consent to participate in the study.
Measurement of FFAs
Plasma samples collected at the 1992 to 1993 examination were stored at −70°C until analyzed at the Central Laboratory at the University of Vermont in 2010. FFA concentrations were measured in duplicate by the Wako enzymatic method, and the average of the 2 measurements was used in current analyses. This technique uses the acylation of coenzyme A by the fatty acids in the presence of added acyl-CoA synthetase. Acyl-CoA produced is oxidized by added acyl-CoA oxidase with generation of hydrogen peroxide, which in the presence of peroxidase permits the oxidative condensation of 3-methyl-N-ethyl-N(β-hydroxyethyl)-aniline with 4-aminoantipyrine to form a purple colored adduct. The latter was then measured colorimetrically at 550 nm. We observed an intra-assay coefficient of variation of 5%.
Ascertainment of HF
In CHS, all potential HF events were adjudicated by the CHS Events Committee as previously described. 32, 33 Briefly, HF validation required a constellation of symptoms (shortness of breath, fatigue, orthopnea, paroxysmal nocturnal dyspnea); pulmonary edema and increasing cardiomegaly on chest radiographs; clinical signs such as edema, pulmonary rales, gallop rhythm, and displaced LV apical impulse; and treatment of HF using diuretics, digitalis, or vasodilators. Incident HF was ascertained on review of pertinent data on hospitalization or outpatient visits such as medical history, physical examination, report of chest radiograph, and medications. The determination of systolic versus diastolic HF was based on LVEF (LVEF <55% and ≥55%, respectively). LVEF was obtained from an echocardiogram, cardiac catheterization, multiple gated cardiac pool imaging, or other modality. There were adequate data to estimate LVEF on 608 (47%) of the HF events in our sample, of whom 386 cases with HF had LVEF<55% (systolic HF), and 222 cases with HF had LVEF ≥55% (diastolic HF). The current analysis included validated HF through June 30, 2009.
Other Variables
Information on age, sex, ethnicity, years of education, physical activity, smoking status, and alcohol consumption was based on self-report. The leisure-time activity (kcal/wk) was assessed with a modified Minnesota Leisure-Time Activities questionnaire. 34 Weight, waist circumference, and height were measured using standardized protocols. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. The measure of self-reported weight loss >10 lbs was supplemented by actual weight loss for the white cohort.
Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or treatment with antihypertensive medications. Diabetes mellitus was defined if a participant was using insulin or oral hypoglycemic agents; had a fasting glucose level of ≥7 mmol/L (126 mg/dL) or a nonfasting glucose level of ≥11.1 mmol/L (200 mg/dL). Glomerular filtration rate was estimated based on cystatin C as previously described. 35 
Statistical Methods
Characteristics of eligible participants who did and did not develop HF were summarized using means and SDs, medians, and interquartile ranges (for highly skewed variables), or counts and proportions. Cumulative incidence of HF by tertile of FFAs was examined using Kaplan-Meier estimates, and a Tarone test was used to test for a trend across tertiles. The shape of the association of plasma FFA with incident HF was examined in Cox models using penalized cubic splines. 36 A likelihood ratio test revealed no meaningful departures from linearity, and thus FFAs were subsequently analyzed linearly. We developed sequential models, initially adjusting for age, sex, race, and field center; and subsequently for a number of potential confounding variables including education, BMI, estimated glomerular filtration, physical activity, alcohol intake, smoking, hormone replacement therapy in women, serum albumin, unintentional weight loss, and self-reported health status. We also examined potential mediation effects by repeating primary analysis using incident coronary heart disease (CHD) and diabetes mellitus as time-dependent variables. Assumptions of proportional hazards were tested using Schoenfeld goodness-of-fit test.
In secondary analyses, we tested for effect modification by sex, adiposity, time-varying CHD, and diabetes mellitus status. We used competing risk models to assess whether the association between FFAs and HF differed based on pathogenesis of HF (systolic versus diastolic). 37 In a sensitivity analysis, we repeated the main analyses restricted to the first 5 years of follow-up because a single measure of FFA might not capture changes in plasma FFAs over many years. Additionally, we explored cross-sectional associations of FFAs with BNP, troponin, and echocardiographic assessed LV mass indices to explore possible biological mechanisms of the association. All analyses were performed with STATA version 11.0 (College Station, TX) and R version 2.13.0 (http://www.r-project.org).
Results
The mean age of the 4248 study participants at baseline (1992-1993) was 74.7 years (range, 65-98 years). During a median follow-up of 10.5 years, a total of 1286 (30%) participants developed HF. Baseline characteristics of study population are shown in Table 1 . Participants who developed HF during follow-up were more likely to be men and less physically active; had lower estimated glomerular filtration and high-density lipoprotein cholesterol, and had higher BMI, systolic blood pressure, triglycerides, c-reactive protein, and NT-proBNP; and had a higher prevalence of atrial fibrillation, hypertension, coronary heart disease, and diabetes mellitus ( Table 1) .
Higher tertile of FFAs was associated with a higher incidence rate of congestive heart failure (P=0.02; Figure) . In a Cox proportional hazard model adjusting for age, sex, race, and clinic, each SD (0.2 mEq/L) higher plasma FFA was associated with 13% (95% confidence interval [CI], 6%-19%) higher risk of HF (P<0.001; Table 2 ). Additional adjustment for education, BMI, estimated glomerular filtration, leisure-time physical activity, hormone replacement therapy (women), alcohol intake, self-reported general health status, smoking, unintentional weight loss, and serum albumin did not alter the findings (corresponding hazard ratio [HR], 1.12 [95% CI, 1.06-1.19]; Table 2 ). Adding plasma phospholipid α-linoleic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid did not alter the conclusion (HR, 1.15 [95% CI, 1.08-1.23]). Further adjustment for lipid-lowering drugs, diuretics, β-blockers, and angiotensin-converting enzyme inhibitors did not alter the results (data not shown). Further adjustment for atrial fibrillation and N-terminal probrain natriuretic peptide did not alter the conclusion (HR, 1.12 [1.05-1.20]; P=0.001). Findings were similar in a secondary analysis controlling for time-varying diabetes mellitus and coronary heart disease (HR per SD, 1.16 [1.09-1.23]; Table 3 ), and adjustment for total adiponectin did not alter the findings. Results were not modified by (1) the presence or absence of coronary artery disease before incident HF (P value for inter-action=0.16) or (2) congestive heart failure with preserved versus poor LVEF (P value for interaction=0.23). There was no evidence of interaction between FFAs and sex, BMI, waist to hip ratio, or prevalent diabetes mellitus (all P>0.05). FFAs were weakly associated with NT-proBNP (Spearman correlation coefficient=0.05; P=0.02) but not with troponin (Spearman correlation coefficient=0.00; P=0.88).
Discussion
In this prospective cohort of older US adults, we found evidence in support of a positive association between plasma FFAs and incident HF after adjustment for known risk factors for HF, including atrial fibrillation and brain natriuretic peptide. The observed association of FFAs with HF did not differ by type of HF (systolic versus diastolic HF) or the presence of antecedent coronary heart disease (P value for interac-tion=0. 16 ). Finally, sex, BMI, waist to hip ratio, and prevalent diabetes mellitus did not modify the FFA-HF relation.
To the best of our knowledge, this is the first study to examine whether plasma FFA concentration is associated with incident HF in a large cohort of elderly men and women. Despite a lack of data on the relation of FFAs with HF risk, earlier studies have reported associations between FFAs and risk factors for HF including hypertension, atrial fibrillation, diabetes mellitus, and CHD, thereby lending support to a causal of FFA-HF association. Specifically, plasma concentrations of FFAs were shown to be higher in spontaneous hypertensive rats compared with control rats. 38 In the Paris Prospective Study 39 of 2968 nonhypertensive and nondiabetic white men, fasting plasma FFA concentration was associated with a 58% higher risk of hypertension (95% CI, 30% to 91%) comparing the 90th with the 10th percentile in a multivariable adjusted model. In a cross-sectional study, plasma FFA concentration was positively associated with systolic blood pressure in 343 nondiabetic subjects. 40 Elevated FFAs caused by intralipid infusion in 16 middle-aged women (mean age, 39 years) were associated with elevated systolic blood pressure compared with basal state. 41 FFAs could contribute to the development of hypertension via multiple pathways including α-adrenergic stimulation, endothelial dysfunction, heightened oxidant stress, and stimulation of vascular cell growth as reviewed by Sarafidis and Bakris. 42 FFAs could also increase the risk of HF through the development of coronary artery disease. However, data on FFA-CHD in the literature are inconsistent. In a cross-sectional study, plasma FFAs were positively associated with CHD. 40 Furthermore, 8-hour plasma FFAs after an oral fat load, but not fasting plasma FFAs, were shown to correctly identify patients with CHD (28 male patients with CHD confirmed by angiograms versus 25 male controls). 43 However, in the Paris Prospective study, FFA concentrations were not associated with CHD death on adjustment for traditional risk factors. 44 Because the multivariable model in that study included blood pressure variable that could be a potential mediator between FFAs and CHD, it is uncertain whether FFA is a major predictor of CHD death.
FFA levels have been associated with other risk factors for HF. Previous data from our cohort showed an increased risk of atrial fibrillation (adjusted HR, 1.29 [95% CI, 1.08-1.55], comparing the highest with the lowest quartile of FFA) 45 15 Finally, FFA concentrations have also been related to inflammatory cytokines, 46, 47 known to heighten HF risk.
Our study has important limitations. We measured plasma FFAs at a single point in time and after 65 years. Whether repeated measures and evaluation of trajectories of change in FFAs over time may have provided stronger associations with subsequent HF is presently unknown. FFAs measured in people >65 years may not necessarily yield similar results as FFAs measured in younger adults. We cannot exclude the possibility that residual or unmeasured confounding could partially or completely account for observed association given the observational study design. A large proportion of our study sample was white older adults, thereby limiting the generalizability of our findings to other ethnic or younger age groups. We only had data on LVEF at the time of incident HF for 590 subjects to differentiate systolic from diastolic HF. Finally, we did not have data on natriuretic peptide on all subjects to fully examine the influence of NT-proBNP on the FFA-HF relation.
Conversely, the current study has numerous strengths including a large number of study participants, data on both men and women, a representative US sample of older adults, use of a valid and reproducible method to assess plasma FFA, a standardized and complete adjudication of HF and comorbidities, long-term follow-up, and availability of data on numerous potential confounders.
Plasma FFA can be easily measured in a clinical setting and at relatively lower costs. Hence, if our findings were confirmed in future studies, plasma FFA could help identify older adults at risk for HF and prompt clinicians for a closer monitoring, preventive measures including weight control, proper diet, and physical activity.
In conclusion, we demonstrate for the first time that plasma FFA concentrations are independently associated with incident HF in older adults. Given the current epidemic of obesity, aging population, and high prevalence, morbidity, and mortality of HF, future studies are warranted to determine mechanisms linking FFAs with HF, and to determine whether effects of physical activity, diet, and weight loss on FFAs may help explain associated benefits on HF risk.
